Abstract: A method of selecting a treatment for a subject having cancer is disclosed. The method comprises: (a) determining a level of catalytic activity of at least one DNA repair enzyme in a biological sample of the subject; and (b) selecting an immune checkpoint regulator as a treatment for a subject having a statistically significant different level of catalytic activity of said DNA repair enzyme as compared to the catalytic activity of said DNA repair enzyme in a biological sample of a healthy subject.

Abstract: Methods and kits for determining a risk of a subject, or subjects for developing lung cancer is disclosed. The method comprises determining a level of catalytic activity of N-methylpurine DNA glycosylase (MPG), or apurinic/apyrimidinic endonuclease 1 (APE1), or both, or MPG and 8-oxoguanine DNA glycosylase (OGG1), or MPG and APE1 and OGG1 in peripheral blood cells of a subject, wherein levels of MPG above a predetermined reference value, or APE1 or OGG1, or a integrated DNA repair score below a predetermined reference value is indicative of an increased risk of developing lung cancer.

Abstract: Methods and kits for determining a risk of a subject, or subjects for developing lung cancer is disclosed. The method comprises determining a level of catalytic activity of N-methylpurine DNA glycosylase (MPG), or apurinic/apyrimidinic endonuclease 1 (APE1), or both, or MPG and 8-oxoguanine DNA glycosylase (OGG1), or MPG and APE1 and OGG1 in peripheral blood cells of a subject, wherein levels of MPG above a predetermined reference value, or APE1 or OGG1, or a integrated DNA repair score below a predetermined reference value is indicative of an increased risk of developing lung cancer.

Abstract: Methods and kits for (i) determining a risk of a subject to develop cancer; (ii) evaluating an effectiveness and dosage of cancer therapy administered to a cancer patient; and (iii) determining a presence of correlation or non-correlation between an activity of at least one DNA repair enzyme and at least one cancer, are disclosed.

Abstract: Methods and kits for (i) determining a risk of a subject to develop cancer; (ii) evaluating an effectiveness and dosage of cancer therapy administered to a cancer patient; and (iii) determining a presence of correlation or non-correlation between an activity of at least one DNA repair enzyme and at least one cancer, are disclosed.

Abstract: A device, system and method for molecular computing which not only includes a suitable, renewable power source, but actually is able to receive power through the performance of the computations themselves. The molecular computing machine of the present invention actually employs the free-energy difference between its input and output to accomplish a computation, preferably by using its input DNA molecule as a partial source of energy, or alternatively by using the input DNA molecule as the sole source of energy. This molecular finite automaton preferably transforms an input DNA molecule into an output DNA molecule by digesting the input as it computes.

Abstract: A device, system and method for molecular computing which not only includes a suitable, renewable power source, but actually is able to receive power through the performance of the computations themselves. The molecular computing machine of the present invention actually employs the free-energy difference between its input and output to accomplish a computation, preferably by using its input DNA molecule as a partial source of energy, or alternatively by using the input DNA molecule as the sole source of energy. This molecular finite automaton preferably transforms an input DNA molecule into an output DNA molecule by digesting the input as it computes.

Abstract: Methods and kits for (i) determining a risk of a subject to develop cancer; (ii) evaluating an effectiveness and dosage of cancer therapy administered to a cancer patient; and (iii) determining a presence of correlation or non-correlation between an activity of at least one DNA repair enzyme and at least one cancer, are disclosed.

Abstract: Methods and kits for (i) determining a risk of a subject to develop cancer; (ii) evaluating an effectiveness and dosage of cancer therapy administered to a cancer patient; and (iii) determining a presence of correlation or non-correlation between an activity of at least one DNA repair enzyme and at least one cancer, are disclosed.